Skip to main content
Terug
Watch Compare

Vivani Medical, Inc.

Datakwaliteit: 83%
VANI
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 1,04
€ 0,00 (0,00%)
Marktkapitalisatie: 87,61 M
Prijs
€ 1,04
Marktkapitalisatie
87,61 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -25,49 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-855,73%
Onder sectorgemiddelde (-53,53%)
ROIC-107,76%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,61
Interest CoverageN/A

Waardering

PE (TTM)
-3,29
Onder sectorgemiddelde (-1,48)
P/B Ratio66,93
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -3,3 -1,5
P/B 66,9 1,6
ROE % -855,7 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 1,04
+364.7%
Koersdoel
€ 4,83
€ 3,50
€ 4,00
€ 7,00
Vooruitzicht
Forward WPA -€ 0,38
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,38
-€ 0,38 – -€ 0,38
 0,0 1
FY2026 -€ 0,35
-€ 0,35 – -€ 0,35
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,09 -€ 0,09 0,0%
Q32025 -€ 0,11 -€ 0,11 0,0%
Q22025 -€ 0,10 -€ 0,12 -20,0%
Q12025 -€ 0,11 -€ 0,11 -4,8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -26,61 M
ROE -855,73% ROA -98,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -25,49 M
ROIC -107,76% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,61
Interest Coverage N/A Asset Turnover N/A
Working Capital -2,66 M Tangible Book Value 1,31 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,29 Forward P/E N/A
P/B Ratio 66,93 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -29,10%
Market Cap 87,61 M Enterprise Value 84,98 M
Per Share
EPS (Diluted TTM) -0,43 Revenue / Share N/A
FCF / Share -0,30 OCF / Share -0,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 95,81%
SBC-Adj. FCF -26,98 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -26,61 M -23,49 M -25,65 M -13,89 M -8,92 M
EPS (Diluted) -0,43 -0,43 — — —
Gross Profit — — — — 130.000,0
Operating Income -27,56 M -24,68 M -26,97 M -21,24 M -8,93 M
EBITDA — — — — —
R&D Expenses 18,13 M 15,75 M 16,97 M 14,17 M 2,37 M
SG&A Expenses — — — — —
D&A 424.000,0 400.000,0 357.000,0 381.000,0 70.000,0
Interest Expense — — — — —
Income Tax 2.000,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 39,39 M 41,56 M 45,80 M 51,13 M 70,88 M
Total Liabilities 23,66 M 23,95 M 25,04 M 6,82 M 2,51 M
Shareholders' Equity 15,73 M 17,61 M 20,76 M 44,31 M 68,37 M
Total Debt — — — — —
Cash & Equivalents 16,23 M 18,35 M 20,65 M — 69,59 M
Current Assets 17,90 M 20,44 M 23,06 M 47,53 M 70,51 M
Current Liabilities 6,60 M 5,99 M 5,72 M 6,82 M 2,46 M